复方鳖甲软肝片联合恩替卡韦对HBV相关肝硬化患者的效果分析(1)
【摘要】 目的 分析復方鳖甲软肝片联合恩替卡韦对乙型肝炎病毒(HBV)相关肝硬化患者的效果。方法 96例HBV相关肝硬化患者， 按照临床应用的治疗方案不同分成对照组(44例)和医治组(52例)。
对照组单纯行恩替卡韦治疗， 医治组联合复方鳖甲软肝片治疗， 对比两组医治前后肝功能与乙型肝炎病毒的脱氧核糖核酸(HBV-DNA)定量及肝纤维化指标变化情况。结果 医治前， 医治组的丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)与HBV-DNA分别为(258.76±132.51)U/L、(47.28±16.53)μmol/L、(5.86±0.81)copies/ml， 对照组分别为(257.18±114.28)U/L、(47.05±17.52)μmol/L、(5.91±0.63)copies/ml；
医治后， 医治组的ALT、TBIL与HBV-DNA分别为(55.26±19.13)U/L、(22.16±8.75)μmol/L、(3.21±
1.06)copies/ml， 对照组分别为(67.52±17.21)U/L、(30.04±10.74)μmol/L、(3.78±1.40)copies/ml。两组医治后的ALT、TBIL与HBV-DNA均较医治前显著下降， 且医治组下降的幅度优于对照组， 差异具有统计学意义(P<0.05)。两组医治后Ⅳ型胶原(CⅣ)、透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)及层粘连蛋白(LN)均较医治前降低， 且医治组降低幅度较对照组更大， 差异均具有统计学意义(P<0.05)。结论 HBV相关肝硬化患者行复方鳖甲软肝片联合恩替卡韦治疗在改善其肝功能及肝纤维化方面疗效显著， 值得临床推广应用。
【关键词】 复方鳖甲软肝片；恩替卡韦；乙型肝炎病毒相关肝硬化
DOI：10.14163/j.cnki.11-5547/r.2017.23.062
Effect analysis of Fufang Biejia Ruangan tablets combined with entecavir for HBV related cirrhosis patients WANG Qing-ling. Department of Infectious Diseases， Shandong Liaocheng Chiping County People’s Hospital， Liaocheng 252100， China
【Abstract】 Objective To analyze the effect of Fufang Biejia Ruangan tablets combined with entecavir for hepatitis B virus (HBV) related cirrhosis patients. Methods A total of 96 HBV related cirrhosis patients were divided by different treatment regimens into control group (44 cases) and treatment group (52 cases). The control group was treated with entecavir， and the treatment group was treated with Fufang Biejia Ruangan tablets. Comparison were made on liver function， hepatitis B virus desoxyribonucleic acid (HBV-DNA) quantitative and liver fibrosis index changes before and after treatment in two groups. Results Before treatment， the treatment group had alanine aminotransferase (ALT)， total bilirubin (TBIL) and HBV-DNA respectivelyas (258.76±132.51) U/L，(47.28±16.53) μmol/L and (5.86±0.81) copies/ml， which were (257.18±114.28) U/L， (47.05±17.52) μmol/L， (5.91±0.63) copies/ml in the control group. After treatment， the treatment group had ALT， TBIL and HBV-DNA respectively as (55.26±19.13) U/L， (22.16±8.75) μmol/L and (3.21±1.06) copies/ml， which were (67.52±17.21) U/L，(30.04±10.74) μmol/L and (3.78±1.40) copies/ml in the control group. Both groups had lower ALT， TBIL and HBV-DNA than before treatment， and the treatment better decline degree than the control group. Their difference had statistical significance (P<0.05). After treatment， both groups had lower type Ⅳ collagen (CⅣ)， hyaluronic acid (HA)， type Ⅲ procollagen (PC-Ⅲ) and laminin (LN) than before treatment， and the treatment group had higher decline degree than the control group. Their difference had statistical significance (P<0.05). Conclusion Combination of Fufang Biejia Ruangan tablets and entecavir shows remarkable efficacy in improving liver function and hepatic fibrosis for HBV related cirrhosis patients， and it is worthy of clinical promotion and application., http://www.100md.com(王庆玲)
对照组单纯行恩替卡韦治疗， 医治组联合复方鳖甲软肝片治疗， 对比两组医治前后肝功能与乙型肝炎病毒的脱氧核糖核酸(HBV-DNA)定量及肝纤维化指标变化情况。结果 医治前， 医治组的丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)与HBV-DNA分别为(258.76±132.51)U/L、(47.28±16.53)μmol/L、(5.86±0.81)copies/ml， 对照组分别为(257.18±114.28)U/L、(47.05±17.52)μmol/L、(5.91±0.63)copies/ml；
医治后， 医治组的ALT、TBIL与HBV-DNA分别为(55.26±19.13)U/L、(22.16±8.75)μmol/L、(3.21±
1.06)copies/ml， 对照组分别为(67.52±17.21)U/L、(30.04±10.74)μmol/L、(3.78±1.40)copies/ml。两组医治后的ALT、TBIL与HBV-DNA均较医治前显著下降， 且医治组下降的幅度优于对照组， 差异具有统计学意义(P<0.05)。两组医治后Ⅳ型胶原(CⅣ)、透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)及层粘连蛋白(LN)均较医治前降低， 且医治组降低幅度较对照组更大， 差异均具有统计学意义(P<0.05)。结论 HBV相关肝硬化患者行复方鳖甲软肝片联合恩替卡韦治疗在改善其肝功能及肝纤维化方面疗效显著， 值得临床推广应用。
【关键词】 复方鳖甲软肝片；恩替卡韦；乙型肝炎病毒相关肝硬化
DOI：10.14163/j.cnki.11-5547/r.2017.23.062
Effect analysis of Fufang Biejia Ruangan tablets combined with entecavir for HBV related cirrhosis patients WANG Qing-ling. Department of Infectious Diseases， Shandong Liaocheng Chiping County People’s Hospital， Liaocheng 252100， China
【Abstract】 Objective To analyze the effect of Fufang Biejia Ruangan tablets combined with entecavir for hepatitis B virus (HBV) related cirrhosis patients. Methods A total of 96 HBV related cirrhosis patients were divided by different treatment regimens into control group (44 cases) and treatment group (52 cases). The control group was treated with entecavir， and the treatment group was treated with Fufang Biejia Ruangan tablets. Comparison were made on liver function， hepatitis B virus desoxyribonucleic acid (HBV-DNA) quantitative and liver fibrosis index changes before and after treatment in two groups. Results Before treatment， the treatment group had alanine aminotransferase (ALT)， total bilirubin (TBIL) and HBV-DNA respectivelyas (258.76±132.51) U/L，(47.28±16.53) μmol/L and (5.86±0.81) copies/ml， which were (257.18±114.28) U/L， (47.05±17.52) μmol/L， (5.91±0.63) copies/ml in the control group. After treatment， the treatment group had ALT， TBIL and HBV-DNA respectively as (55.26±19.13) U/L， (22.16±8.75) μmol/L and (3.21±1.06) copies/ml， which were (67.52±17.21) U/L，(30.04±10.74) μmol/L and (3.78±1.40) copies/ml in the control group. Both groups had lower ALT， TBIL and HBV-DNA than before treatment， and the treatment better decline degree than the control group. Their difference had statistical significance (P<0.05). After treatment， both groups had lower type Ⅳ collagen (CⅣ)， hyaluronic acid (HA)， type Ⅲ procollagen (PC-Ⅲ) and laminin (LN) than before treatment， and the treatment group had higher decline degree than the control group. Their difference had statistical significance (P<0.05). Conclusion Combination of Fufang Biejia Ruangan tablets and entecavir shows remarkable efficacy in improving liver function and hepatic fibrosis for HBV related cirrhosis patients， and it is worthy of clinical promotion and application., http://www.100md.com(王庆玲)